Summary Tamoxifen is an effective agent preventing mammary carcinogenesis in rats but causing liver tumours. Idoxifene is a more potent antioestrogen and is effective in patients with advanced breast cancer. We therefore compared the effects of idoxifene with tamoxifen on mammary carcinogenesis and hepatic DNA adduct formation. To do this, we undertook a study designed to compare tamoxifen with idoxifene as a chemopreventive agent in rats inoculated with Mmethyinitrosourea (MNU) and also measured hepatic adduct formation. We examined the time to mammary tumour development in 272 female Ludwig/Wistar/Olac rats treated with MNU followed by tamoxifen (5 mg kg-'), equimolar idoxifene or vehicle three times a week for up to 24 weeks. To determine duration of effect, a second study was carried out whereby all of the 129 animals surviving at the end of treatment were entered into a surveillance programme for 27 weeks after the end of the administration period. Hepatic DNA adduct formation was examined by 32P-postlabelling in a group of rats after 24 weeks' treatment. In the first study, both idoxifene and tamoxifen were effective in preventing tumour growth as only 2 out of 21 (10%) MNU and vehicle-treated animals were alive and tumour free after 24 weeks compared with 13 out of 22 (59%) animals receiving MNU followed by idoxifene or tamoxifen (P < 0.001). The second study showed that, in both idoxifene-and tamoxifen-treated animals, a progressive regrowth of tumours occurred after cessation of therapy, as by the end of the observation period only four idoxifene-treated animals and one tamoxifen-treated animal were free from disease. In the subset of animals tested, tamoxifen-treated animals had approximately 100 times higher levels of DNA hepatic adducts than idoxifene-treated animals. Adducts were not seen in the control group. These results indicate that idoxifene is as effective a chemopreventive agent as tamoxifen in the rat while causing only very low levels of DNA adducts in liver tissue and suggest that idoxifene may be a well-tolerated chemopreventive agent in women who are at increased risk of breast cancer.
Tamoxifen, currently used in the treatment of patients with breast cancer, has been shown to reduce the incidence of contralateral breast cancer in women who have been treated for primary breast cancer (EBCTCG, 1992) . These results provided the impetus for the use of tamoxifen to attempt to prevent the development of breast cancer in women who are at high risk (Powles et al, 1989) . However, tamoxifen is associated with uterine carcinogenesis and there are an estimated one or two cases of uterine carcinoma annually per 1000 women treated (Seoud et al, 1993) . Although not known to cause liver tumours in humans, there is evidence that tamoxifen is a hepatic carcinogen in rats, possibly related to the metabolism of tamoxifen to cx-hydroxytamoxifen, a metabolite with high DNA-binding activity (Phillips et al, 1994a, b) . This metabolite is also found in breast cancer patients receiving tamoxifen (Poon et al, 1995) . For these reasons, much work has been done to develop novel antioestrogens. These include LY117018 (Scholl et al, 1983) , droloxifene (Bruning, 1992) , toremifene (Vogel et al, 1993) and ICI 182, 780 (Wakeling, 1991) , the last one showing properties of a pure antioestrogen. Some of these compounds would be unsuitable as preventive agents. Thus, a pure antioestrogen such as ICI 182, 780 might cause osteoporosis, and LY 117018 is rapidly conjugated and excreted (Scholl et al, 1983) . However, both toremifene and droloxifene might be suitable. Each causes little or no DNA formation in the liver, in contrast to tamoxifen, when administered to rats (White et al, 1992) , which could imply a potentially better safety profile for these newer analogues. Recently, we have developed another antioestrogen structurally related to tamoxifen, named idoxifene, and have reported its evaluation in a phase I clinical trial (Coombes et al, 1995) . This compound has lower oestrogenic but greater antioestrogenic activity than tamoxifen (Chander et al, 1991) .
In addition, iodination of the molecule at the 4-position, as well as reducing oestrogenic activity, also blocks 4-hydroxylation and hence subsequent inactivation by glucuronidation (McCague et al, 1990 ). Idoxifene shows a 2.5-to 5-fold higher affinity for the oestrogen receptor (ER) compared with tamoxifen and was 1.5-fold more effective in inhibiting oestrogen-induced growth of MCF-7 cells (McCague et al, 1990; Chander et al, 1991) . In rats bearing N-methylnitrosourea (MNU)-induced mammary tumours, idoxifene was more effective in causing tumour regression (Chander et al, 1991) . Rat hepatocytes metabolize idoxifene 2.5 times more slowly than tamoxifen and rats have a doubling of the terminal half-life of idoxifene compared with tamoxifen (Haynes et al, 1991) . Preclinical toxicology of idoxifene was carried out and this showed, in a single-dose study in mice at 100 mg kg-', no mortality or behaviourial change. Histology showed mild vacuolation of the interstitial cells in the ovary and mild dilatation of the uterine glands but no other abnormality. A repeat-dose study of up to 50 mg kg-1 per dose for 4 weeks showed mild reduction in weight, reduced uterine and ovarian weight, and ovarian interstitial hyperplasia. No other abnormality was seen (Coombes et al, 1995) . For all these reasons, we felt that idoxifene might be a candidate for a chemoprevention agent for breast cancer. To assess the potential of idoxifene we carried out a series of studies in rats, in which mammary tumour formation had been initiated by MNU, to compare its effects with those of tamoxifen in this system.
MATERIALS AND METHODS
Design of chemoprevention studies An initial study was carried out in order to determine the magnitude of the effect of idoxifene in rats in which mammary tumour induction had been initiated by MNU. In this study, 143 rats were randomized to receive idoxifene, tamoxifen or vehicle alone and tumour size was monitored over various periods of time. One batch consisted of 38 animals that were treated for 12 weeks and then killed; a second consisted of 40 animals that were treated for 18 weeks before killing and a third consisted of 65 animals and these were killed at 24 weeks.
We then carried out a second study with 129 animals with prolonged follow-up beyond the end of treatment (batch 4). Animals were treated for 24 weeks and those surviving were followed up for a further 27 weeks before the animals that were still alive were killed.
Animals
In-bred virgin female (Ludwig/Wistar/Olac) rats that had been treated with MNU were supplied by Olac, Oxon, UK. The model used was as described previously (Chander et al, 1991) . Briefly, 45-to 55-day-old rats were induced with three inoculations of 0.5 ml of MNU (50 mg kg-1 body weight) via the tail vein over a period of 6 weeks. Tumours were expected to occur 12-16 weeks after the first inoculation. In this study 272 adult virgin female rats, each weighing about 200 g, commenced treatment 7 weeks after the first inoculation with MNU. Each batch of rats was randomly allocated into three groups for treatment with idoxifene, tamoxifen or vehicle respectively. Charing Cross and Westminster Medical School's institutional guidelines for animal welfare were followed in these experiments.
Drug administration and tumour measurement
Idoxifene was synthesized as described previously (McCague et al, 1989) and tamoxifen was a gift from Dr A Wakeling (Zeneca, UK). Idoxifene and tamoxifen were dissolved in peanut oil. Dosages were at concentrations equimolar to 5 mg of tamoxifen per kg rat body weight at each injection. Drugs (or vehicle) were administered subcutaneously 3 days per week for 12-24 weeks in batches 1-5 (see below). All rats were weighed at the start of the experiment and once every 3 weeks thereafter. Tumours were aNumber includes one animal that had a tumour .10 mm at 9 weeks but that had disappeared at 12 weeks. bOne rat in each group was culled because of haemorrhage but there was no evidence of tumour 2 5 mm.
British Journal of Cancer (1997) 76(6), [700] [701] [702] [703] [704] 0 Cancer Research Campaign 1997 measured in two diameters. In batches 4 and 5, after the twentyfourth week had elapsed, dosing was stopped but weight and tumour measurements continued every 3 weeks for a further 27 weeks. Rats were culled at the onset of tumour ulceration or if any tumour diameter exceeded 30 mm, or at the end of the study. Upon death of an animal, the liver and tumours were removed, snapfrozen and stored at -70°C for later analysis. Rats were also examined at post-mortem for evidence of tumour formation elsewhere. Measurement of adduct formation DNA was isolated from homogenized rat liver using the phenol-chloroform extraction method described previously (Gupta, 1984) . 32P-postlabelling analysis, using the nuclease P, digestion method of sensitivity enhancement, was carried out as described previously (White et al, 1992) , except that apyrase was not used to terminate the labelling reaction. Labelled adducts were resolved by multidirectional thin-layer chromatography (TLC) on polyethyleneimine-cellulose sheets (White et al, 1992) 
RESULTS

Prevention of tumour growth and duration of effect
Overall, at 24 weeks the abilities of tamoxifen and idoxifene to prevent tumorigenesis appear similarly effective when compared with controls ( Figure 1 , P < 0.001).
A E E Table 1 shows the status of treated animals at the different time points. Thus, at 12 weeks, only 23 out of 48 (48%) of control animals were alive and tumour free, whereas 41 out of 48 (85%) and 40 out of 47 (85%) of the idoxifene-and tamoxifen-treated animals respectively, were alive and tumour free at this stage. At 18 weeks, 22 out of 33 (67%) (idoxifene) and 24 out of 36 (67%) (tamoxifen) were tumour free compared with only 9 out of 36 (25%) control animals. At 24 weeks, idoxifene-and tamoxifentreated groups had equal numbers of animals that were tumour free (13 out of 22) (59%). In contrast, only 2 out of 21 (10%) vehicletreated animals were still tumour free at 24 weeks.
The second study (Table 2) confirmed that both idoxifene and tamoxifen provide substantial protection from tumorigenesis with 21 out of 44 (48%) and 24 out of 44 (55%) animals remaining tumour free at 24 weeks respectively, compared with only 6 out of 41 (15%) control animals. When data from batches 1-4 are combined, results for idoxifene and tamoxifen are similar at 12, 18 and 24 weeks with 85%, 67% and 59% of animals alive and tumour free at each of these time points. At 36 and 42 weeks, a greater number of idoxifene-treated animals had died but this is not statistically significant. Animals died from progressive tumour growth with very few exceptions (see footnote to Table 2 ).
To determine the duration of this effect after withdrawal of treatment, we examined the development of tumours in each group, subdividing the analysis into the first 24 weeks (on treatment) and the subsequent 27 weeks (post treatment) (Figure 2A,  B) . Figure 2A shows the tumour development on treatment for batch 4. Figure 2B includes only those animals that were tumour free (i.e. no tumour > 10 mm) at the end of treatment and shows the post-treatment development of tumours. The data indicate that during the post-treatment period there is progressive tumour development in both tamoxifen-and idoxifene-treated animals.
At the end of the 27-week observation period, only four idoxifene-treated animals and one tamoxifen-treated animal were alive and free from disease; similarly one control animal showed no evidence of tumour at this time.
If we consider the time taken to develop large tumours (more than 15 mm diameter) only, and using all available data, a similar proportion (54%) of idoxifene-treated animals developed large tumours compared with tamoxifen-treated animals, and there was a suggestion that the time taken to develop these tumours may be longer for tamoxifen than idoxifene-treated animals (Figure 3 ).
Adduct formation in livers of treated and control animals
No tumours, other than mammary tumours, were observed during the study, but we compared the effects of tamoxifen, idoxifene and vehicle on adduct formation in liver tissues of treated animals. Fifteen livers (five from each treatment group) were obtained from animals culled after the 24-week treatment period. No adducts were detected in the control liver DNA (Figure 4) . Two of the five idoxifene-treated animals showed no evidence of adduct formation but three showed a very low adduct level, with a chromatographic mobility similar to that of the major tamoxifen adduct. The values for the five idoxifene samples (mean of two determinations, expressed as adducts per 108 nucleotides) were calculated to be 0, 0, 11.0, 8.4 and 10.2.
In contrast to these two groups, adducts were detected in all tamoxifen-treated animals. The levels (expressed as adducts per 108 nucleotides) were 596, 1059, 644, 533 and 708. The adduct profiles were typical of tamoxifen adducts in liver and in vitro (Phillips et al, 1994 a, b) (Figure 4 ).
DISCUSSION
Our results show that idoxifene is similar to tamoxifen in its ability to suppress tumorigenesis in rats treated with MNU. Essentially, both drugs suppressed tumour formation during the period of administration: when treatment was withdrawn the tumour incidence gradually rose to control levels. Thus, at the end of the 27-week observation period, nearly all animals had palpable tumours. In the presence of large tumours (2 15 mm) it was obligatory to cull animals if the tumour burden became too great. This, therefore, precludes a reliable analysis of survival. The nearest surrogate is the time to occurrence of a tumour of 2 15 mm. This analysis suggests that tamoxifen may be superior to idoxifene in this regard, but the difference failed to achieve statistical significance. These results confirm several other groups' results demonstrating the preventative effect of tamoxifen on tumour growth (Jordan, 1993) but are the first to show that idoxifene has a similar effect. The study also demonstrates that a potential benefit of idoxifene compared with tamoxifen is its substantially lower ability to form hepatic DNA adducts in rats in vivo, indicating that liver tumorigenesis is unlikely to be a long-term side effect in a prevention strategy. The reason for the reduced adduct formation observed with idoxifene is still not clear. However, there is a major interspecies difference in idoxifene metabolism between rats and humans with the 4'-hydroxy derivative of idoxifene being the major metabolite in rats in vitro and in vivo (Vogel et al, 1993) . This metabolite is so far undetected in human plasma (Coombes et al, 1995) . There is a similar situation with tamoxifen in which 4-hydroxylation is a major metabolite in rodents but only a minor circulating metabolite in humans (unpublished results). However, the a-hydroxylated compound seems to be the major compound responsible for hepatic carcinogenesis of tamoxifen in rats (Phillips et al, 1994a, b) and differences in the extent of its formation may go some way to explaining the observed differences in hepatic adduct formation between the two species. Although idoxifene is also ax-hydroxylated by rat hepatocytes (Haynes et al, 1991) it forms DNA adducts at levels two orders of magnitude lower than those formed by tamoxifen. It has been suggested ) that both athydroxylation and 4-hydroxylation may be needed for maximal adduct formation. Moreover, the activation mechanism proposed would not operate for a 4'-hydroxy derivative. Hence, idoxifene may be an intrinsically safer alternative to tamoxifen in the preventative setting.
Our previous study (Coombes et al, 1995) has shown that, in humans, there are other important quantitative differences between tamoxifen and idoxifene in that the latter has an approximately three-fold longer terminal half-life. Idoxifene also has a 50% lower clearance rate than tamoxifen. A further important feature of idoxifene, previously demonstrated by our group (Chander et al, 1991) , is its reduced uterotrophic activity in rats. In this earlier study we demonstrated that, after 21 days treatment, the uterine weight was significantly reduced when compared with tamoxifen (P = 0.006). Despite this, 10 mg kg-' idoxifene was capable of inhibiting the oestradiolinduced uterotrophic effect. Further, when analysed in a vaginal cornification assay, idoxifene failed to reveal any oestrogenic activity. Again, idoxifene was able, unlike tamoxifen, to completely block oestradiol-induced comification. Thus, although the current study did not specifically address the issue of idoxifene-induced uterine neoplasia, it seems probable that such effects will be less than with tamoxifen.
Other potential side-effects of tamoxifen in chemoprevention have been summarized (Powles et al, 1989 ) and the placebocontrolled preventative study has been reported previously (Powles et al, 1990) . The majority of subjective side-effects reported in the phase I study of idoxifene by our group seem very similar to those of tamoxifen (Coombes et al, 1995) although further, longer term assessment in patients is required to assess effects on plasma lipids, bone density and the retina.
